Endo Health Solutions (ENDP) 8-K Bear Stearns Healthcare Conference

ENDO PHARMACEUTICALS

Bear Stearns Healthcare Conference

September 11, 2007

Exhibit 99.1

Accelerating Our Growth

©

2007 Endo Pharmaceuticals

Forward-Looking Statements

Except

for

the

historical

information

contained

herein,

this

presentation

contains

“forward-looking

statements”

within

the

meaning

of

the

Private

Securities

Litigation

Reform

Act

of

1995.

Because

these

statements

involve

a

number

of

risks

and

uncertainties,

actual

future

results

may

differ

materially

from

those

expressed

or

implied

by

such

forward-looking

statements.

Factors

that

could

cause

or

contribute

to

such

differences

include,

but

are

not

limited

to,

the

difficulty

of

predicting

FDA

approvals,

results

of

clinical

trials

on

new

products,

acceptance

and

demand

for

new

pharmaceutical

products,

challenges

relating

to

intellectual

property

protection,

the

impact

of

competitive

products

and

pricing,

the

timely

development

and

launch

of

new

products,

a

determination

that

we

are

engaging

in

inappropriate

sales

or

marketing

activities,

including

promoting

the

"off-label"

use

of

our

products,

and

the

risk

factors

listed

from

time

to

time

in

the

Company’s

SEC

reports,

including

the

Company’s

Annual

Report

on

Form

10-K

for

the

fiscal

year

ended

December

31,

2006.

Accelerating Our Growth

©

2007 Endo Pharmaceuticals

Endo Pharmaceuticals

–

Leader in Pain Management

Specialty pharma company with market leadership in pain

management

•

Analgesics fourth-largest prescription drug market in 2006

with $7.3 billion in reported sales

•

Opioids represented 80% of all analgesic prescriptions

Proven commercial capability

•

Specialty and PCP sales and marketing teams

•

Sales force recently expanded by ~ 95 reps

Pipeline focused on delivery and execution

•

Two NDAs approved in 2006; expect additional sNDA in 2007

Strong financial condition –

no debt

Accelerating Our Growth

©

2007 Endo Pharmaceuticals

Growth Strategy

Evaluate best use of strong balance sheet and cash

position

Further diversify revenue base through product licensing

and acquisitions of other specialty focused companies

Deepen and broaden penetration into the pain market

•

Target clinically innovative and differentiated products while

continuing to advance current development pipeline

Drive top-line growth by maximizing potential of key on-

market products and successfully launching FROVA in MM

indication

Continue to pursue selective development of generic

products

Accelerating Our Growth

©

2007 Endo Pharmaceuticals

Revised 2007 Guidance Upward

$1.75-$1.80

Adjusted Diluted EPS

$90-$110 million

OPANA

®

ER / OPANA

®

Net Sales

$685-$710 million

LIDODERM

®

Net Sales

$1.050-$1.075 billion

Net Sales

Accelerating Our Growth

©

2007 Endo Pharmaceuticals

$0

$200

$400

$600

$800

$1,000

$1,200

2002

2003

2004

2005

2006

2007*

Net Sales

Net Income

Consistent Financial Growth

$399.0

$595.6

$615.1

$820.2

$30.8

$69.8

$143.3

$202.3

$909.7

$1,062.0

$137.8

(millions, except per share)

Diluted EPS           $0.30             $0.53            $1.08 

$1.52             $1.03 **

* Represents mid-point of company guidance       ** Includes $0.62 in one-time, non-cash items

Accelerating Our Growth

©

2007 Endo Pharmaceuticals

Sales Force Expansion

Recently added ~ 95 sales representatives to Specialty

Force II to match size of Specialty Force I

•

Both specialty forces will have approximately 160 reps

Will provide double coverage to broaden reach and

frequency among specialty physicians

•

Pain Management Specialists, Neurologists, Oncologists,

Physical Medicine and Rehabilitation

•

Ensures high frequency on highest-decile (8-10) prescribers

Brings total number of reps to 690; furthers already strong

share of voice in pain management

Provides optimal reach and frequency to promote current

product portfolio

Accelerating Our Growth

©

2007 Endo Pharmaceuticals

$178

$309

$419

$698

$567

$0

$200

$400

$600

$800

2003

2004

2005

2006

2007*

LIDODERM

-

A True Success Story

($ in millions)

*Represents mid-point of company guidance

Accelerating Our Growth

©

2007 Endo Pharmaceuticals

OPANA

Franchise

Accelerating Our Growth

©

2007 Endo Pharmaceuticals

OPANA Update

Scripts (currently 6k per week) on track to meet 2007

guidance

Implemented aggressive managed-care strategy to attain

Tier II parity

Introduced OPANA ER Instant Savings Card Program

Increased promotional and marketing activities

•

Redeployed Specialty Force II

•

Launched new promotional materials

•

Full schedule of peer-to-peer speaker programs

•

Major presence at APS and at upcoming medical conferences

with clinical data presentations

Accelerating Our Growth

©

2007 Endo Pharmaceuticals

OPANA

ER TRx Launch Comparison

Accelerating Our Growth

©

2007 Endo Pharmaceuticals

Development Pipeline

(1) 

Licensed marketing rights   

(2)

Licensed marketing and development rights

Phase I

Phase II

Phase III

Filed

Pre-

clinical

Undisclosed

Sufentanil Patch

(2)

(Transdermal -

Chronic Pain)

EN 3285

(Oral

Rinse

for

Oral

Mucositis)

RAPINYL

TM (2)

(Breakthrough

Cancer

Pain)

Ketoprofen Patch

(2)

(Topical

-

Soft

Tissue

Injuries)

FROVA

®

(1)

(Menstrual Migraine)

Product

Accelerating Our Growth

©

2007 Endo Pharmaceuticals

FROVA

MM Prophylaxis:

Exciting Near-Term Opportunity

PDUFA date extended beyond 8/19/07

•

New action date 9/30/07

•

No additional information requested by FDA

Substantial clinical data package submitted, including:

•

Two statistically significant Phase III, double-blind, placebo-

controlled studies

•

Long-term open-label safety and tolerance study

Accelerating Our Growth

©

2007 Endo Pharmaceuticals

FROVA MM Market Development

Would be first triptan with short-term (six days) prevention

claim

Requires paradigm shift from acute care to short-term

prophylaxis

Pre-launch campaign underway to raise MM awareness

•

Extensive physician education program

•

Targeted on-line DTP initiatives

•

Journal ads

Accelerating Our Growth

©

2007 Endo Pharmaceuticals

Summary

Market leader in pain management

Well-developed commercial capability

Very broad and deep pipeline

Strong financial condition

Clear

strategy for sustainable growth

ENDO PHARMACEUTICALS

Nasdaq: ENDP